ChromaDex Corp. Sample Contracts

ChromaDex Corp. – ChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for TRU NIAGEN® (December 20th, 2018)

ChromaDex Corporation and Nestlé Health Science agreement includes global commercial license and supply agreement for ingredient sales of TRU NIAGEN® for certain products within the medical nutrition and consumer health categories.

ChromaDex Corp. – ChromaDex Corporation Amended and Restated Non-Employee Director Compensation Policy Adopted: November 8, 2016 Amended and Restated: November 16, 2016 Amended and Restated: April 6, 2017 Amended and Restated: June 22, 2018 Effective Date: July 3, 2016 (August 9th, 2018)

Each member of the Board of Directors (the “Board”) who is a member as of November 8, 2016 or thereafter and who is not also serving as an employee of ChromaDex Corporation (“ChromaDex”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (the “Director Compensation Policy”) for his or her Board service.

ChromaDex Corp. – AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (June 28th, 2018)

This Amendment (this “Amendment”) to the Amended and Restated Employment Agreement, dated April 19, 2010 (the “Employment Agreement”), by and between ChromaDex, Inc., a California corporation (and a wholly-owned subsidiary of ChromaDex Corporation) (the “Company”) and Frank L. Jaksch, Jr. (“Executive”), is entered into as of June 22, 2018 by and among the Company and Executive. Capitalized terms used herein which are not defined in this Amendment shall have the meanings as ascribed to them in the Employment Agreement.

ChromaDex Corp. – ChromaDex Corporation 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 Amended by the Board of Directors: April 24, 2018 Approved by the Stockholders: June 22, 2018 (June 28th, 2018)
ChromaDex Corp. – CHROMADEX CORPORATION AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for ROBERT FRIED (June 28th, 2018)

This Amended and Restated Executive Employment Agreement (this “Agreement”) is entered into as of June 22, 2018 (the “Effective Date”), by and between Robert Fried (“Executive”) and ChromaDex Corporation, a Delaware corporation (the “Company”).

ChromaDex Corp. – ChromaDex Corporation 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 (March 15th, 2018)
ChromaDex Corp. – CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT for MARK FRIEDMAN (March 15th, 2018)

This Executive Employment Agreement (this “Agreement”) is entered into as of January 22, 2018 (the “Effective Date”), by and between Mark Friedman (“Executive”) and ChromaDex Corporation, a Delaware corporation (the “Company”).

ChromaDex Corp. – ChromaDex Corporation 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 Amended by the Board of Directors: January 21, 2018 (January 23rd, 2018)
ChromaDex Corp. – Transition and Separation Agreement (December 21st, 2017)

This letter sets forth the terms and conditions of our agreement (“Agreement”) regarding the separation of your employment with ChromaDex Corporation and its subsidiaries, including Chromadex, Inc. (collectively, the “Company”), and the transition services you will provide. This Agreement will become effective on the Effective Date as defined in Section 10 herein. Capitalized terms that are used in this Agreement, but not defined herein, shall have the meanings ascribed to them in the Amended and Restated Employment Agreement between you and the Company, dated April 10, 2010 (the “Employment Agreement”).

ChromaDex Corp. – CHROMADEX CORPORATION AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (December 21st, 2017)

This Amendment to Executive Employment Agreement (this “Amendment”), amending that certain Executive Employment Agreement dated March 12, 2017 (the “Employment Agreement”), by and between ChromaDex Corporation, a Delaware corporation (the “Company”), and Robert Fried (the “Executive”), is entered into as of December 20, 2017 by and among the Company and the Executive. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Employment Agreement.

ChromaDex Corp. – FIFTH BUSINESS FINANCING MODIFICATION AGREEMENT (November 9th, 2017)

This Fifth Business Financing Modification Agreement (this “Agreement”) is entered into as of August 21, 2017, by and among CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTICS, INC., a Nevada corporation, HEALTHSPAN RESEARCH LLC, a Delaware limited liability company (each, a “Borrower” and collectively, “Borrowers”), and WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”).

ChromaDex Corp. – REGISTRATION RIGHTS AGREEMENT (November 6th, 2017)

This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of November 3, 2017 by and among ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”).

ChromaDex Corp. – SECURITIES PURCHASE AGREEMENT (November 6th, 2017)

This Securities Purchase Agreement (this “Agreement”) is dated as of November 3, 2017, between ChromaDex Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

ChromaDex Corp. – CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT for KEVIN M. FARR (October 10th, 2017)

This Executive Employment Agreement (this “Agreement”) is entered into as of October 5, 2017 (the “Effective Date”), by and between Kevin M. Farr (“Executive”) and ChromaDex Corporation, a Delaware corporation (the “Company”).

ChromaDex Corp. – THIRD BUSINESS FINANCING MODIFICATION AGREEMENT (August 10th, 2017)

This Third Business Financing Modification Agreement (this “Agreement”) is entered into as of April 19, 2017, by and among CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTICS, INC., a Nevada corporation (“Existing Borrowers”) and HEALTHSPAN RESEARCH LLC, a Delaware limited liability company (“New Borrower”, and together with Existing Borrowers, each, a “Borrower” and collectively, “Borrowers”), and WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”).

ChromaDex Corp. – ChromaDex Corporation Amended and Restated Non-Employee Director Compensation Policy Adopted: November 8, 2016 Amended and Restated: November 16, 2016 Amended and Restated: April 6, 2017 Effective Date: July 3, 2016 (August 10th, 2017)

Each member of the Board of Directors (the “Board”) who is a member as of November 8, 2016 or thereafter and who is not also serving as an employee of ChromaDex Corporation (“ChromaDex”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (the “Director Compensation Policy”) for his or her Board service.

ChromaDex Corp. – FOURTH BUSINESS FINANCING MODIFICATION AGREEMENT (August 10th, 2017)

This Fourth Business Financing Modification Agreement (this “Agreement”) is entered into as of July 13, 2017, by and among CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTICS, INC., a Nevada corporation and HEALTHSPAN RESEARCH LLC, a Delaware limited liability company (each, a “Borrower” and collectively, “Borrowers”), and WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”).

ChromaDex Corp. – LICENSE AGREEMENT (August 10th, 2017)

This License Agreement is effective as of June 5, 2017 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation ("TSRI"), and ChromaPharma, Inc. a Nevada corporation ("Licensee"), each located at the respective address set forth in Section 13.17 below, with respect to the facts set forth below.

ChromaDex Corp. – RESEARCH FUNDING AGREEMENT by and between THE SCRIPPS RESEARCH INSTITUTE a California nonprofit public benefit corporation and ChromaPharma, Inc. A Nevada corporation RESEARCH FUNDING AGREEMENT (August 10th, 2017)

This Agreement is entered into this 5th day of June, 2017 (the “Effective Date”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037 ("TSRI"), and ChromaPharma, Inc., a Nevada for-profit corporation located at 10005 Muirlands Blvd., Suite G, Irvine, CA 92618 USA ("Sponsor"), with respect to the facts set forth below.

ChromaDex Corp. – ChromaDex Corporation 2017 Equity Incentive Plan Adopted by the Board of Directors: April 6, 2017 Approved by the Stockholders: June 20, 2017 (June 23rd, 2017)
ChromaDex Corp. – ChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN® in treating breast cancer (June 12th, 2017)

This acquisition brings the total number of patents and patents pending relating to nicotinamide riboside, owned or exclusively licensed by ChromaDex, to 16.

ChromaDex Corp. – FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (May 25th, 2017)

THIS FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”), dated as of May 24, 2017, is entered into by and among ChromaDex Corporation, a Delaware corporation (the “Company”), Champion River Ventures Limited (“Champion River”) and Pioneer Step Holdings Limited (“Pioneer Step” and together with Champion River, the “Purchasers”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement (as defined below).

ChromaDex Corp. – ChromaDex Corporation Restricted Stock Award Grant Notice (Second Amended and Restated 2007 Equity Incentive Plan) (May 11th, 2017)

ChromaDex Corporation (the “Company”), pursuant to its Second Amended and Restated 2007 Equity Incentive Plan (as amended from time-to-time, the “Plan”), hereby awards to Participant a restricted stock award covering the number of shares of the Company’s Common Stock set forth below. The Company acknowledges the receipt from Participant of consideration with respect to the par value of the shares of the Company’s Common Stock in the form of cash, past or future services rendered to the Company by Participant or such other form of consideration as is acceptable to the Board. The restricted stock award and the shares of Common Stock awarded hereunder are subject to all of the terms, conditions and restrictions as set forth herein, in the Restricted Stock Award Agreement and the Plan, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Restricted Stock Award Agreement will have the same

ChromaDex Corp. – MEMBERSHIP INTEREST PURCHASE AGREEMENT (May 11th, 2017)

THIS MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Agreement”) is made as of March 12, 2017, by and among (i) Robert N. Fried, an individual (“R. Fried”), (ii) Dr. Charles Brenner, an individual (“Dr. Brenner”), (iii) Jeffrey Allen, an individual (“J. Allen”; each of R. Fried, Dr. Brenner, and J. Allen, a “Seller”, and collectively the “Sellers”), and ChromaDex Corporation, a Delaware corporation (“Buyer”). Sellers and Buyer are collectively referred to herein as the “Parties” and each individually as a “Party.”

ChromaDex Corp. – REGISTRATION RIGHTS AGREEMENT (May 2nd, 2017)

This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of April 29, 2017 by and among ChromaDex Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several purchasers signatory hereto (each, a “Purchaser” and collectively, the “Purchasers”).

ChromaDex Corp. – SECURITIES PURCHASE AGREEMENT (April 27th, 2017)

This Securities Purchase Agreement (this “Agreement”) is dated as of April 26, 2017, between ChromaDex Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

ChromaDex Corp. – ChromaDex Corporation Amended and Restated Non-Employee Director Compensation Policy Adopted: November 8, 2016 Amended and Restated: November 16, 2016 Effective Date: July 3, 2016 (March 16th, 2017)

Each member of the Board of Directors (the “Board”) who is a member as of November 8, 2016 or thereafter and who is not also serving as an employee of ChromaDex Corporation (“ChromaDex”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (the “Director Compensation Policy”) for his or her Board service.

ChromaDex Corp. – CHROMADEX CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT (March 16th, 2017)

This Executive Employment Agreement (the “Agreement”) is entered into by and between ChromaDex Corporation, a Delaware corporation (the “Company”) and Robert Fried (the “Executive”), effective as of the Effective Date (as defined below). The Company and Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.

ChromaDex Corp. – BUSINESS FINANCING AGREEMENT (March 16th, 2017)

This BUSINESS FINANCING AGREEMENT, dated as of November 4, 2016, is made and entered into between WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”) and CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTICS, INC., a Nevada corporation and SPHERIX CONSULTING, INC., a Delaware corporation (each, a “Borrower” and collectively, “Borrowers”) on the following terms and conditions:

ChromaDex Corp. – SECOND BUSINESS FINANCING MODIFICATION AGREEMENT (March 16th, 2017)

This Second Business Financing Modification Agreement (this “Agreement”) is entered into as of March 12, 2017, by and among CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTICS, INC., a Nevada corporation, (each, a “Borrower” and collectively, “Borrowers”) and WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”).

ChromaDex Corp. – FIRST BUSINESS FINANCING MODIFICATION AGREEMENT (March 16th, 2017)

This First Business Financing Modification Agreement (this “Agreement”) is entered into as of February 16, 2017, by and among CHROMADEX CORPORATION, a Delaware corporation, CHROMADEX, INC., a California corporation, CHROMADEX ANALYTICS, INC., a Nevada corporation, (each, a “Borrower” and collectively, “Borrowers”) and WESTERN ALLIANCE BANK, an Arizona corporation (“Lender”).

ChromaDex Corp. – INDEMNITY AGREEMENT (December 16th, 2016)

This Indemnity Agreement (this “Agreement”) dated as of ___________ _____, 20__, is made by and between ChromaDex Corporation, a Delaware corporation (the “Company”), and _________________ (“Indemnitee”).

ChromaDex Corp. – FIRST AMENDMENT TO THE LICENCE AGREEMENT (November 10th, 2016)

THIS FIRST AMENDMENT to the LICENSE AGREEMENT with an Effective Date of October 15, 2014 is made as of this July 6, 2015 (“Effective Date of the Amendment”), by and between the UNIVERSITY OF MISSISSIPPI, and CHROMADEX, INC. concerning a blue green algae technology.

ChromaDex Corp. – EXCLUSIVE LICENSE AGREEMENT PREAMBLE (November 10th, 2016)

This Agreement is made and entered into, effective as of March 4, 2013, (“Effective Date”) by and between: Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as "WU"); and Chromadex a corporation organized and existing under the laws of the State of California, having its principal offices at 10005 Muirlands Blvd. Suite G Irvine CA 92618 (hereinafter referred to as "Licensee") and the following correspondence addresses:

ChromaDex Corp. – LICENSE AGREEMENT (November 10th, 2016)

THIS LICENSE AGREEMENT is made as of this 1st Day of August 2013 (“Execution Date”) by and between the GREEN MOLECULAR S.L., a Spanish corporation with a principal address at Parc Cientific Universidad de Valencia, Polígono La Coma s/n, 46980 Paterna, Valencia, Spain (“GM”) and Chromadex, Inc. , a corporation organized and existing under the laws of California with a principal address 10005 Muirlands Bvld Suite G, Irvine , California 92618 (“CHROMADEX”)